The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and ...

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today ...

Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of ...